Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma

Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma

On November 23, 2015, the US Food and Drug Administration (FDA) approved nivolumab for the treatment of metastatic renal cell carcinoma (RCC), thus opening a new era of immunotherapy for this tumor. This review summarizes the 5-year experience of studying and using nivolumab in RCC patients.

Saved in:
Bibliographic Details
Published in:Kidney Cancer Vol. 5; no. 2; pp. 63 - 71
Main Author: Tsimafeyeu, Ilya
Format: Book Review Journal Article
Language:English
Published: London, England SAGE Publications 16-06-2021
Subjects:
metastatic renal cell carcinoma
Nivolumab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On November 23, 2015, the US Food and Drug Administration (FDA) approved nivolumab for the treatment of metastatic renal cell carcinoma (RCC), thus opening a new era of immunotherapy for this tumor. This review summarizes the 5-year experience of studying and using nivolumab in RCC patients.
ISSN:2468-4562
2468-4570
DOI:10.3233/KCA-200109